Oncotelic Therapeutics, Inc. (OTLC)

OTCMKTS · Delayed Price · Currency is USD
0.0464
+0.0005 (1.20%)
At close: Feb 27, 2026
20.83%
Market Cap 20.49M
Revenue (ttm) n/a
Net Income (ttm) -1.67M
Shares Out 441.58M
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 252,844
Average Volume 388,841
Open 0.0480
Previous Close 0.0459
Day's Range 0.0440 - 0.0490
52-Week Range 0.0150 - 0.1100
Beta -0.64
RSI 31.92
Earnings Date Apr 13, 2026

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications. It develops antisense and small molecule injectable drugs for the treatment of cancer. The company is also developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; OT-101, an antisense against TGF-β2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as for the treatment of various viruses, including severe acute resp... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Vuong Trieu
Employees 26
Stock Exchange OTCMKTS
Ticker Symbol OTLC
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.